Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Candidate NRTX-1001 at Neuroscience 2021
November 08, 2021 08:00 ET | Neurona Therapeutics
IND cleared by the FDA to enable initiation of Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant focal epilepsy Supporting preclinical data demonstrate seizure-freedom in up to 68%...
Former U.S. Congressman Fattah Calls for African Brain Research Fund During Global Neuroscience Conference
October 28, 2021 17:57 ET | Fattah Neuroscience Global Advisors
Accra, Ghana / Philadelphia, PA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Today, former United States Congressman and CEO of Fattah Neuroscience Global Advisors, Chaka Fattah, delivered a powerful virtual...
logo.png
Nexstim’s SmartFocus® TMS Technology Used in Award-Winning Project Addressing Disorders of Consciousness after Severe Brain Injury
October 15, 2021 02:00 ET | Nexstim Oyj
Press release, Helsinki, 15 October 2021 at 9 AM (EEST) Nexstim’s SmartFocus® TMS Technology Used in Award-Winning Project Addressing Disorders of Consciousness after Severe Brain Injury Nexstim Plc...
compass_positive_tagline-01.png
Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds
September 10, 2021 07:00 ET | COMPASS Pathfinder Ltd.
      COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris,...
compass_positive_tagline-01.png
Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training
July 21, 2021 07:00 ET | COMPASS Pathfinder Ltd.
      London, UK – 21 July 2021         COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)
July 07, 2021 12:51 ET | Ischemix, Inc.
GRAFTON, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Ischemix, Inc., a private company focused on developing therapeutics for serious medical conditions, today announced that the US Department of...
compass_positive_tagline-01.png
COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme
June 23, 2021 07:00 ET | COMPASS Pathfinder Ltd.
Programme aims to support students from under-represented ethnic groups London, UK – 23 June 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to...
TrevenaLogo.jpg
Trevena, Inc. to Participate at the Sachs Associates 4th Annual Neuroscience Innovation Forum
April 29, 2021 07:00 ET | Trevena Inc.
CHESTERBROOK, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central...
Sensory Challenges and Anxiety in Children with and without Autism - A Free Webinar from the Brain & Behavior Research Foundation
March 02, 2021 09:00 ET | Brain & Behavior Research Foundation
New York, March 02, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Sensory Challenges and Anxiety in Children with and without Autism” on...
NOVARTIS logo.jpg
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
February 16, 2021 13:23 ET | Novartis International AG
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction...